Iron Chelation Therapy as a Modality of Management
dc.contributor.author | Aydinok, Yesim | |
dc.date.accessioned | 2019-10-27T10:41:55Z | |
dc.date.available | 2019-10-27T10:41:55Z | |
dc.date.issued | 2018 | |
dc.department | Ege Üniversitesi | en_US |
dc.description.abstract | Introduction of MRI techniques for identifying and monitoring tissue iron overload and the current understanding of iron homeostasis in transfusion-dependent (TDT) and non transfusion-dependent thalassemia have allowed for a more robust administration of iron chelation therapies. The development of safe and efficient oral iron chelators and the insights gained from large-scale prospective studies using these agents have improved iron overload management. A significant reduction in iron toxicity induced morbidity and mortality and improvements in quality of life were observed in TDT. The appropriate management of tissue-specific iron loading in TDT has been portrayed using evidence-based data obtained from investigational studies. | en_US |
dc.description.sponsorship | Novartis Pharmaceuticals; Cerus; Celgene; Shire | en_US |
dc.description.sponsorship | Receiving research grant funding, consulting fees, and lecture fees from Novartis Pharmaceuticals, research grant funding and lecture fees from Cerus, research grant funding from Celgene and Shire. | en_US |
dc.identifier.doi | 10.1016/j.hoc.2017.12.002 | en_US |
dc.identifier.endpage | + | en_US |
dc.identifier.issn | 0889-8588 | |
dc.identifier.issn | 1558-1977 | |
dc.identifier.issue | 2 | en_US |
dc.identifier.pmid | 29458731 | en_US |
dc.identifier.scopusquality | Q2 | en_US |
dc.identifier.startpage | 261 | en_US |
dc.identifier.uri | https://doi.org/10.1016/j.hoc.2017.12.002 | |
dc.identifier.uri | https://hdl.handle.net/11454/30551 | |
dc.identifier.volume | 32 | en_US |
dc.identifier.wos | WOS:000428462100010 | en_US |
dc.identifier.wosquality | Q2 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.language.iso | en | en_US |
dc.publisher | W B Saunders Co-Elsevier Inc | en_US |
dc.relation.ispartof | Hematology-Oncology Clinics of North America | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Thalassemia major | en_US |
dc.subject | Thalassemia intermedia | en_US |
dc.subject | Transfusion-dependent thalassemia | en_US |
dc.subject | Non-transfusion dependent thalassemia | en_US |
dc.subject | Chelation | en_US |
dc.subject | Liver iron concentration | en_US |
dc.subject | Cardiac iron | en_US |
dc.subject | Serum ferritin | en_US |
dc.title | Iron Chelation Therapy as a Modality of Management | en_US |
dc.type | Article | en_US |